Key Takeaways
- Margin squeeze from raw materials, not demand: Consolidated revenue grew 12% YoY in H1, but EBITDA and PAT margins compressed under an unprecedented rise in Chrome ore and Barytes costs, plus a 22-day scheduled plant shutdown.
- The Barium business is the bright spot: Barium delivered one of its highest PATs in 12 quarters, with EBITDA margins exceeding 16.75%, driven by process improvements, a better product mix, and the Ramadas Minerals acquisition.
- Two acquisitions reset the strategic chessboard: A South African chrome mine promises to make Vishnu the lowest-cost global producer of Chromium derivatives, while Jayansree Pharma opens a new vertical in import-substitute Strontium chemistry.
- Export headwinds were absorbed, not amplified: Management shifted volumes to the domestic market to offset a subdued export environment, and sea freight volatility, though painful in Q2, has started to ease.
- What to watch next quarter: Whether the high-cost chrome ore inventory spillover into Q3 keeps Chromium margins pinned, and if the promised 100-200 bps Barium margin expansion materializes.
Margin Walk: The Raw Material Shock
- Chrome ore and Barytes spike: An unprecedented price rise in both minerals was the primary margin headwind, overwhelming the benefit of lower soda ash prices.
- High-cost inventory overhang: Chrome ore is imported quarterly, so the high-cost inventory will spill over into Q3, but management stated it will not extend beyond Q3.
- Chromite ore price relief is coming: The ore price has declined, mainly on a sea freight adjustment, and this benefit will reflect in the P&L from Q4.
- Scheduled shutdown amplified fixed costs: A 22-day maintenance shutdown at the Vizag plant incurred fixed costs without production, though revenue was protected by higher finished goods inventory built in prior quarters.
- One-time acquisition costs: Administrative expenses tied to the acquisitions were expensed in Q2 and will not recur.
- Chromium gross margin floor: Despite subdued export demand and logistics cost pressure on end-product prices, backward integration completed two years ago is holding Chromium gross margins at roughly 40%.
Hanumant Bhansali: "The EBITDA margins for the subsidiary business is expected to improve and from the current levels of around 16.75%, we expect it to increase over the next two quarters by 100 to 200 basis points."
Barium: The Standout Performer
- Profitability at a multi-quarter high: The Barium business achieved one of its highest PATs in 12 quarters, with EBITDA margins exceeding 16.75%, supported by process improvements, a diversified product mix, and operating leverage.
- PBS volume growth target intact: Management expects volume growth close to 40% for FY25 versus FY24, with a solid order book for H2.
- Capacity doubling planned: The company plans to double Precipitated Barium Sulfate capacity from the current 30,000 tons (at 80-90% operating level) to at least 50,000 tons by FY27.
- Ramadas Minerals integration paying off: The prior-year acquisition reduced the overall cost of production in the Barium vertical, contributing to the improved product mix and higher plant utilization.
- Revenue improvement expected: Barium chemicals revenues are expected to improve through the rest of the financial year.
Siddartha Cherukuri: "We are planning to double the capacity by FY '27 of Precipitated Barium Sulfate. Currently which we are seeing is 30,000 tons considering operating level of 80% to 90%. We will have to take it up to 60,000 tons considering the operating level of 80%."
Strategic Acquisitions: The Mine and the New Molecule
- South Africa chrome mine: In November 2024, Vishnu entered a definitive agreement to acquire a Chrome Mining Complex through a subsidiary, with closure expected within 12 months, subject to regulatory approvals.
- Lowest-cost producer ambition: The mine is expected to improve consolidated EBITDA margins by at least 2% to 3% at full operating level and make Vishnu the lowest-cost producer globally for all Chromium derivatives.
- Phased self-sufficiency: The plan is to source 100% of chrome ore requirements in a phased manner, with the mine partially operating and feeding a sizable volume by H2 FY26, and full self-sufficiency targeted by end-FY26 or H1 FY27.
- Mine condition de-risks restart: The mine was kept in very good condition during care and maintenance, with manpower still employed, so the investment to restore operations will not be substantial.
- Jayansree Pharma and Strontium: The August 2024 acquisition marks a foray into Strontium Chemistry, producing Strontium Carbonate, a complete import substitute with no other Indian producer. Production starts Q1 FY26.
- Strontium revenue potential: At full operating level of 10,000 tons, two years down the line, the Strontium business is expected to generate ₹140 to ₹150 crore of revenue.
Siddartha Cherukuri: "It's a complete import substitute. Right now there is no other player that's producing this in India."
Demand and Logistics: Managing the Export Drag
- Export slowdown absorbed: A subdued export market was mitigated by shifting more volumes to the domestic market, maintaining overall market share.
- Sea freight volatility easing: Sea freights were volatile with an upward trend in Q2 but have come down and stabilized by end-Q3, though not yet to pre-Red Sea levels. Management hopes for a return to pre-Red Sea levels by Q4.
- Logistics as a compounding headwind: Demand pressure did not aggravate sequentially, but logistical challenges added to the existing demand pressure as a separate headwind.
- Improved demand environment anticipated: Management expects an improved demand environment during FY26, aided by logistics costs coming down.
- Inventory build is structural, not a red flag: Higher inventory levels versus historical years reflect higher raw material prices and increased transit times, with management deliberately maintaining more inventory of both raw materials and finished goods to meet customer requirements.
New Products and the Growth Algorithm
- Chromium metal launch: A new value-added product, Chromium metal, will be launched during Q1 FY26.
- 20% growth objective: Management's stated objective is to grow at least 20% year-on-year, though they acknowledge revising guidance in challenging years like the current one.
- Global market share ambition: Management sees an international market share of 8% to 12-13% as "very likely to happen," per an analyst's reference.
- Financial improvement timeline: Management expects things to fall in place by H2 FY26, with the mining complex and chrome metal driving improvement in both revenue and EBITDA margin.
- Chrome ore sales to third parties: In the short-to-medium term, no third-party ore sales are planned as the priority is stabilizing operations and feeding internal furnaces; medium-to-long term, some material might be available to market.
Siddartha Cherukuri: "Our objective is to grow at least at a 20% level year-on-year. Maybe in certain challenging years like this, we have to revise our guidance, but I think our idea is to grow and be sustainable as we move forward."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Barium EBITDA margin expansion | Increase by 100 to 200 bps from current ~16.75% | Next two quarters |
| PBS volume growth | Close to 40% for FY25 vs FY24 | FY25 |
| PBS capacity doubling | From 30,000 tons to at least 50,000 tons (at 80% operating level) | By FY27 |
| Chrome mine commercial production | Partially operating, feeding sizable volume | H2 FY26 |
| Chrome mine full self-sufficiency | 100% of chrome ore requirement sourced internally | End-FY26 to H1 FY27 |
| Chrome mine margin impact | Improve consolidated EBITDA margins by at least 2% to 3% | At full operating level |
| Chromium metal launch | New value-added product | Q1 FY26 |
| Strontium Carbonate production start | Via Jayansree Pharma acquisition | Q1 FY26 |
| Strontium Carbonate revenue | ₹140 to ₹150 crore | At full 10,000-ton operating level, two years down the line |
| Chromite ore cost relief | Lower ore price to reflect in P&L | Q4 FY25 |
| High-cost chrome ore inventory spillover | Will not extend beyond Q3 | Q3 FY25 |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Consolidated operating revenue | ₹343.8 cr, +12% YoY |
| Consolidated gross profit | ₹147 cr, +6% YoY |
| Consolidated EBITDA | ₹45.1 cr, -2% YoY |
| Consolidated PAT | ₹22.8 cr, -5% YoY |
| H1 FY25 consolidated operating revenue | ₹682.7 cr, +12% YoY |
| H1 FY25 consolidated EBITDA | ₹100.8 cr, +4% YoY |
| H1 FY25 consolidated PAT | ₹53.3 cr, +1% YoY |
| Domestic-to-export sales mix | 57:43, driven by robust domestic demand |
| Consolidated debt-to-equity ratio | 0.45x |
| Barium business EBITDA margin | >16.75% in Q2 FY25, expected to improve 100–200 bps over next two quarters |
| Precipitated Barium Sulfate volume growth guidance | ~40% for FY25 vs FY24 |
| Precipitated Barium Sulfate plant utilization | 65%–70%, de-bottlenecking underway to reach 80%–90% |
| Chromium chemicals capacity | 80,000 tons per annum (Sodium dichromate basis) |
| Barium chemicals total capacity | ~90,000 tons per annum (Barium Carbonate 60,000 tons, Precipitated Barium Sulfate 30,000 tons) |
| Chromium chemicals market share in India | ~50% |
| Precipitated Barium Sulfate market share in India | ~30%, expanded from ~15% last year; sole manufacturer in India |
| Scheduled maintenance shutdown | 22 days in Q2, 8 days remaining over FY25 |
| Chrome mine acquisition expected EBITDA margin uplift | 2%–3% at full operating level |
| Jayansree Pharma enterprise value | ₹51.99 cr, gross block ~₹80 cr, net block >₹50 cr |
| Strontium Carbonate peak revenue potential | ₹140–150 cr at full 10,000-ton operating level, two years out |